Related Experiment Video
Updated: Jul 9, 2025

Author Spotlight: Exploring Strategies for Successful Immune Response Against Tumors
Published on: August 16, 2024
Personalized tumor combination therapy optimization using the single-cell transcriptome
Chen Tang1, Shaliu Fu1,2, Xuan Jin1
1Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University), Ministry of Education, Orthopaedic Department of Tongji Hospital, Frontier Science Center for Stem Cell Research, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Background:
The precise characterization of individual tumors and immune microenvironments using transcriptome sequencing has provided a great opportunity for successful personalized cancer treatment. However, the cancer treatment response is often characterized by in vitro assays or bulk transcriptomes that neglect the heterogeneity of malignant tumors in vivo and the immune microenvironment, motivating the need to use single-cell transcriptomes for personalized cancer treatment.
Methods:
Here, we present comboSC, a computational proof-of-concept study to explore the feasibility of personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC provides a workable solution to stratify individual patient samples based on quantitative evaluation of their personalized immune microenvironment with single-cell RNA sequencing and maximize the translational potential of in vitro cellular response to unify the identification of synergistic drug/small molecule combinations or small molecules that can be paired with immune checkpoint inhibitors to boost immunotherapy from a large collection of small molecules and drugs, and finally prioritize them for personalized clinical use based on bipartition graph optimization.
Results:
We apply comboSC to publicly available 119 single-cell transcriptome data from a comprehensive set of 119 tumor samples from 15 cancer types and validate the predicted drug combination with literature evidence, mining clinical trial data, perturbation of patient-derived cell line data, and finally in-vivo samples.
Conclusions:
Overall, comboSC provides a feasible and one-stop computational prototype and a proof-of-concept study to predict potential drug combinations for further experimental validation and clinical usage using the single-cell transcriptome, which will facilitate and accelerate personalized tumor treatment by reducing screening time from a large drug combination space and saving valuable treatment time for individual patients. A user-friendly web server of comboSC for both clinical and research users is available at www.combosc.top . The source code is also available on GitHub at https://github.com/bm2-lab/comboSC .
Insights
This study introduces comboSC, a computational tool that uses single-cell transcriptomes to predict optimal personalized cancer drug combinations. It analyzes the immune microenvironment to identify synergistic therapies, accelerating personalized cancer treatment.
Area of Science:
- Computational Biology
- Genomics
- Cancer Research
Background:
- Personalized cancer treatment relies on precise characterization of tumors and immune microenvironments.
- Current methods like in vitro assays or bulk transcriptomes overlook tumor heterogeneity and in vivo immune microenvironments.
- Single-cell transcriptomes are crucial for overcoming these limitations in personalized cancer therapy.
Purpose of the Study:
- To present comboSC, a computational proof-of-concept for optimizing personalized cancer combination therapy.
- To stratify patient samples by evaluating their immune microenvironment using single-cell RNA sequencing.
- To identify synergistic drug combinations and immunotherapy pairings for personalized clinical use.
Main Methods:
- comboSC utilizes single-cell RNA sequencing data to quantitatively assess the immune microenvironment.
- It integrates in vitro cellular response data to identify synergistic drug combinations.
- Bipartition graph optimization is employed to prioritize drug combinations for clinical use.
Main Results:
- comboSC was applied to 119 single-cell transcriptome datasets from 15 cancer types.
- Predicted drug combinations were validated using literature, clinical trial data, cell line perturbations, and in vivo samples.
- The study demonstrates the feasibility of comboSC for predicting effective cancer drug combinations.
Conclusions:
- comboSC is a feasible computational prototype for predicting personalized cancer drug combinations.
- It accelerates personalized tumor treatment by reducing screening time and saving clinical time.
- A web server and source code are available for clinical and research users.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

